BRISTOL-MYERS SQUIBB COMPANY Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax of $5.00 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-10-25.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax · last filed 2018-10-25
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, before tax for the quarter ending 2018-09-30 was $5.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, before tax for the quarter ending 2018-06-30 was $96.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, before tax for the quarter ending 2018-03-31 was -$18.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, before tax for the quarter ending 2017-12-31 was $10.00M, a 94.85% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, before tax for fiscal 2017 was -$82.00M, a 1271.43% decline from fiscal 2016.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, before tax for fiscal 2016 was $7.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, before tax for fiscal 2015 was -$71.00M, a 172.45% decline from fiscal 2014.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, before tax for fiscal 2014 was $98.00M, a 4800.00% increase from fiscal 2013.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax 12 month |
|---|---|---|---|---|
| 2018-09-30 | $5.00M 10-Q · filed 2018-10-25 | $101.00M derived: sum of 2 quarters · filed 2018-10-25 | $83.00M 10-Q · filed 2018-10-25 | $93.00M derived: sum of 4 quarters · filed 2018-10-25 |
| 2018-06-30 | $96.00M 10-Q · filed 2018-07-26 | $78.00M 10-Q · filed 2018-07-26 | $88.00M derived: sum of 3 quarters · filed 2018-07-26 | $81.00M derived: sum of 4 quarters · filed 2018-10-25 |
| 2018-03-31 | -$18.00M 10-Q · filed 2018-04-26 | -$8.00M derived: sum of 2 quarters · filed 2018-04-26 | -$15.00M derived: sum of 3 quarters · filed 2018-10-25 | -$60.00M derived: sum of 4 quarters · filed 2018-10-25 |
| 2017-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $3.00M derived: sum of 2 quarters · filed 2018-10-25 | -$42.00M derived: sum of 3 quarters · filed 2018-10-25 | -$82.00M 10-K · filed 2018-02-13 |
| 2017-09-30 | -$7.00M 10-Q · filed 2018-10-25 | -$52.00M derived: sum of 2 quarters · filed 2018-10-25 | -$92.00M 10-Q · filed 2018-10-25 | $102.00M derived: sum of 4 quarters · filed 2018-10-25 |
| 2017-06-30 | -$45.00M 10-Q · filed 2018-07-26 | -$85.00M 10-Q · filed 2018-07-26 | $109.00M derived: sum of 3 quarters · filed 2018-07-26 | $116.00M derived: sum of 4 quarters · filed 2018-07-26 |
| 2017-03-31 | -$40.00M 10-Q · filed 2018-04-26 | $154.00M derived: sum of 2 quarters · filed 2018-04-26 | $161.00M derived: sum of 3 quarters · filed 2018-04-26 | $97.00M derived: sum of 4 quarters · filed 2018-04-26 |
| 2016-12-31 | $194.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $201.00M derived: sum of 2 quarters · filed 2018-02-13 | $137.00M derived: sum of 3 quarters · filed 2018-02-13 | $7.00M 10-K · filed 2018-02-13 |
| 2016-09-30 | $7.00M 10-Q · filed 2017-10-26 | -$57.00M derived: sum of 2 quarters · filed 2017-10-26 | -$187.00M 10-Q · filed 2017-10-26 | -$192.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | -$64.00M 10-Q · filed 2017-07-27 | -$194.00M 10-Q · filed 2017-07-27 | -$199.00M derived: sum of 3 quarters · filed 2018-02-13 | -$272.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | -$130.00M 10-Q · filed 2017-04-27 | -$135.00M derived: sum of 2 quarters · filed 2018-02-13 | -$208.00M derived: sum of 3 quarters · filed 2018-02-13 | -$209.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | -$5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$78.00M derived: sum of 2 quarters · filed 2018-02-13 | -$79.00M derived: sum of 3 quarters · filed 2018-02-13 | -$71.00M 10-K · filed 2018-02-13 |
| 2015-09-30 | -$73.00M 10-Q · filed 2016-10-27 | -$74.00M derived: sum of 2 quarters · filed 2016-10-27 | -$66.00M 10-Q · filed 2016-10-27 | -$37.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | -$1.00M 10-Q · filed 2016-07-28 | $7.00M 10-Q · filed 2016-07-28 | $36.00M derived: sum of 3 quarters · filed 2017-02-21 | $119.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $8.00M 10-Q · filed 2016-04-28 | $37.00M derived: sum of 2 quarters · filed 2017-02-21 | $120.00M derived: sum of 3 quarters · filed 2017-02-21 | $113.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2014-12-31 | $29.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $112.00M derived: sum of 2 quarters · filed 2017-02-21 | $105.00M derived: sum of 3 quarters · filed 2017-02-21 | $98.00M 10-K · filed 2017-02-21 |
| 2014-09-30 | $83.00M 10-Q · filed 2015-10-27 | $76.00M derived: sum of 2 quarters · filed 2015-10-27 | $69.00M 10-Q · filed 2015-10-27 | $58.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | -$7.00M 10-Q · filed 2015-07-23 | -$14.00M 10-Q · filed 2015-07-23 | -$25.00M derived: sum of 3 quarters · filed 2016-02-12 | -$67.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | -$7.00M 10-Q · filed 2015-04-28 | -$18.00M derived: sum of 2 quarters · filed 2016-02-12 | -$60.00M derived: sum of 3 quarters · filed 2016-02-12 | -$64.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | -$11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | -$53.00M derived: sum of 2 quarters · filed 2016-02-12 | -$57.00M derived: sum of 3 quarters · filed 2016-02-12 | $2.00M 10-K · filed 2016-02-12 |
| 2013-09-30 | -$42.00M 10-Q · filed 2014-10-24 | -$46.00M derived: sum of 2 quarters · filed 2014-10-24 | $13.00M 10-Q · filed 2014-10-24 | $17.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | -$4.00M 10-Q · filed 2014-07-24 | $55.00M 10-Q · filed 2014-07-24 | $59.00M derived: sum of 3 quarters · filed 2015-02-13 | $2.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $59.00M 10-Q · filed 2014-04-29 | $63.00M derived: sum of 2 quarters · filed 2015-02-13 | $6.00M derived: sum of 3 quarters · filed 2015-02-13 | $23.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | -$53.00M derived: sum of 2 quarters · filed 2015-02-13 | -$36.00M derived: sum of 3 quarters · filed 2015-02-13 | -$30.00M 10-K · filed 2015-02-13 |
| 2012-09-30 | -$57.00M 10-Q · filed 2013-10-23 | -$40.00M derived: sum of 2 quarters · filed 2013-10-23 | -$34.00M 10-Q · filed 2013-10-23 | |
| 2012-06-30 | $17.00M 10-Q · filed 2013-07-25 | $23.00M 10-Q · filed 2013-07-25 | ||
| 2012-03-31 | $6.00M 10-Q · filed 2013-04-25 | |||
| 2011-12-31 | $80.00M 10-K · filed 2014-02-14 | |||
| 2010-12-31 | $8.00M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |